A Phase 1 interventional study of GenSci098 and GenSci098 Placebo in Safety, Tolerability and GenSci098, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.
Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 20th largest by planned enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2024, is one of 6 in phase 1, reaches primary completion later than 17 of the 27 other live ones, and was the 28th registered.
200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.
Browse Graves Ophthalmopathy studies →25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–80
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–75
Candid Therapeutics · Sites in China
Ages 18–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
Shanghai Changzheng Hospital · Sites in China
Ages 18–70 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 16 · Phase 4 8
First in 2010; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 64 across the 45 interventional studies, 125 across the 10 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 55 have an industry lead sponsor. The 10 most frequent:
Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 47 are open to participants now.
Changchun GeneScience Pharmaceutical Co., Ltd. has 1 study filed under Graves Ophthalmopathy — fewer than ten, so there is no comparison to draw.
12 of the studies in Graves Ophthalmopathy with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989918Phase 3Minghui Pharmaceutical (Hangzhou) LtdMHB018A Treatment in Patients With Active Thyroid Eye Disease | 2026-12 |
| NCT07113262Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease | 2026-12-31 |
| NCT07211776Phase 3Zai Lab (Shanghai) Co., Ltd.A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease | 2027-03-14 |
| NCT07720635Phase 3Beijing Kanghong Biological Medicine Co., Ltd.A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease | 2027-04 |
| NCT07720648Phase 3Beijing Kanghong Biological Medicine Co., Ltd.A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease | 2027-05 |
Add all 12 to your calendar (.ics) → With an account.
Among the 55 studies in Graves Ophthalmopathy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)
To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants must meet one of the following conditions to be eligible for the study:
Fertile female participants agree, from the start of the screening visit until 300 day after the last dose, to consistently and correctly use one of the following acceptable methods of effective :
1) agree to use a condom plus an effective method of contraception (i.e., hormonal contraception initiated at least 30 days prior to administration; or placement of an IUD or IUS) when engaging in sexual activity with a female partner of from the start of the screening visit until 24 weeks after the last dose and refrain from donating sperm during this period.
2) agree to practice abstinence from the start of the screening visit until 24 weeks after the last dose.
3) have had a vasectomy at least 6 months prior to study treatment. 12. Voluntarily sign the ICF and be able to understand and comply with the study's treatment regimen and assessments until the end of the study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GenSci098
Drug: GenSci098 Placebo
subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.
In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, multiple doses of GenSci098 and GenSci098 Placebo will be given.
Incidence and severity of adverse events (AEs) (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG]).
Time frame: SAD Part: 169 days, MAD Part: 281 days
PK parameters after single and multiple subcutaneous doses of GenSci098: maximum concentration at steady state (Cmax,ss);
Time frame: SAD Part: 169 days, MAD Part: 281 days
PK parameters after single and multiple subcutaneous doses of GenSci098: minimum concentration at steady state (Cmin,ss);
Time frame: SAD Part: 169 days, MAD Part: 281 days
PK parameters after single and multiple subcutaneous doses of GenSci098: time to maximum concentration at steady state (Tmax,ss);
Time frame: SAD Part: 169 days, MAD Part: 281 days
PK parameters after single and multiple subcutaneous doses of GenSci098: average concentration at steady state (Cav,ss);
Time frame: SAD Part: 169 days, MAD Part: 281 days
PK parameters after single and multiple subcutaneous doses of GenSci098: area under the concentration-time curve at steady state (AUC0-τ,ss);
Time frame: SAD Part: 169 days, MAD Part: 281 days
PK parameters after single and multiple subcutaneous doses of GenSci098: apparent clearance CL/F
Time frame: SAD Part: 169 days, MAD Part: 281 days
PK parameters after single and multiple subcutaneous doses of GenSci098: half life t1/2,
Time frame: SAD Part: 169 days, MAD Part: 281 days
Incidences of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs), and titer of ADA.
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interleukin (IL)-6
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interleukin IL-8,
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including monocyte chemotactic protein 1 (MCP-1)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interleukin IL-4
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interleukin IL-10
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interleukin IL-12
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interleukin IL-13
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interleukin IL-17
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interleukin IL-23
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interleukin IL-1β
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including soluble interleukin-1 receptor antagonist (sIL-1RA)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including interferon γ (IFN γ)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including transforming growth factor β (TGF β)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including tumor necrosis factor α (TNF α)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including Chemokine(C-X-C Motif)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum inflammatory cytokines including Ligand 10 (CXCL-10
Time frame: SAD Part: 169 days, MAD Part: 281 days
Change from Baseline in proptosis of the study eye,amount of protrusion of the eye from the orbital rim measured by Hertel exophthalmometer.
Time frame: SAD Part: 169 days, MAD Part: 281 days
Change from Baseline in CAS value of the study eye,composed spontaneous retrobulbar pain, pain on attempted upward or downward gaze,redness of eyelids,redness of conjunctiva,swelling of caruncle or plica,swelling of eyelids,swelling of conjunctiva.
Time frame: SAD Part: 169 days, MAD Part: 281 days
Change from Baseline in diplopia,Diplopia assessment will be performed using the Gorman score
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in GO-QoL.
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum thyrotropin receptor antibody (TRAb),
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in thyroid-stimulating antibody (TSAb)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum total triiodothyronine (T3)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum total thyroxine (T4)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum free triiodothyronine (FT3)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum free thyroxine (FT4)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Changes from baseline in serum thyroid-stimulating hormone (TSH)
Time frame: SAD Part: 169 days, MAD Part: 281 days
Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changchun GeneScience Pharmaceutical Co., Ltd. →